Market Minds Advisory
Preparative and Process Chromatography Market

Preparative and Process Chromatography Market: Continuous Bioprocessing Reshapes Biologics Purification

Biologics manufacturers and contract development organizations across major producing regions are qualifying expanded continuous chromatography capacity as monoclonal antibody volume and process intensification mandates both pull production investment forward faster than most suppliers anticipated.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$4.8BMarket Size 2025
2036 FORECAST VALUE$11.9BBase Case , 2026 to 2036
CAGR 2026 TO 20368.6 %Bull 9.9% / Bear 7.3%
INCREMENTAL OPPORTUNITY$6.7BNet 10- year value creation
EXPANSION MULTIPLE2.28x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Biologics manufacturers and contract development organizations are qualifying expanded continuous chromatography capacity, and that shift is happening considerably faster than most suppliers anticipated as monoclonal antibody volume pulls production investment forward across every major bioprocessing market today, across nearly every producing region and therapeutic category worldwide overall.
North America anchors global demand, home to the deepest biologics manufacturing capacity in the world, as Cytiva, Merck KGaA, and Sartorius AG compete for the same biopharmaceutical manufacturer and contract development organization accounts across an expanding production base. Continuous and multi-column chromatography systems are the fastest-growing category, smaller than standard affinity chromatography volume but the preferred format as process intensification intensifies. Manufacturers increasingly treat that as standard purification practice, specified by default today.
Five suppliers, Cytiva, Merck KGaA, Sartorius AG, Bio-Rad Laboratories Inc, and Repligen Corporation, hold roughly 48 percent of global preparative and process chromatography revenue, a moderate concentration reflecting an industry still populated by numerous specialized resin and system manufacturers. Tightening process intensification demand and expanding single-use adoption are pulling system specification forward across nearly every major biopharmaceutical roadmap, as suppliers accelerate continuous chromatography investment nationwide and across export markets.
Market Definition
The preparative and process chromatography market covers preparative and process-scale liquid chromatography systems, resins, and consumables used for downstream purification of biologics, monoclonal antibodies, vaccines, and small-molecule active pharmaceutical ingredients in commercial and clinical-scale manufacturing. It excludes analytical-scale chromatography instruments used for quality control and research testing, gas chromatography systems, and chromatography media used exclusively in non-pharmaceutical industrial separation applications.
Base Year Value
$4.8B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.6% base case. Bull 9.9%. Bear 7.3%.
Fastest Growth Segment
Continuous and Multi-Column Chromatography Systems: 12.8% CAGR
Fastest Growth Country
China: 11.6% CAGR
Fastest Growth Region
South Asia and Pacific: 10.6% CAGR
Largest Region
North America: 30% of 2025 global value
Market Leaders
Cytiva, Merck KGaA, Sartorius AG, Bio-Rad Laboratories Inc, Repligen Corporation. Source: MMA Analysis based on company annual reports and investor filings.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Preparative and Process Chromatography Market Forecast Scenarios

preparative-and-process-chromatography-market-size-forecast-scenario-1787307669073
Preparative and process chromatography demand grew steadily from 2020 through 2025 as biologics manufacturing capacity recovered from pandemic-era vaccine production disruptions and monoclonal antibody pipeline volume expanded across major biopharmaceutical markets worldwide. The category grew at roughly a 7.9 percent historical compound rate as manufacturers began qualifying expanded continuous chromatography capacity. Growth accelerated meaningfully across the final two years of the period.
MMA's base case assumes 8.6 percent compound growth through 2036, anchored in three mechanisms. First, expanding monoclonal antibody and biosimilar production volume across major biopharmaceutical systems is pulling chromatography demand forward across an increasing number of therapeutic categories. Second, tightening process intensification and cost-of-goods reduction mandates are favouring continuous multi-column systems over conventional batch chromatography. Third, rising single-use bioprocessing adoption is extending demand into facilities that historically relied exclusively on stainless-steel fixed installations.
A bull scenario near 9.9 percent follows if continuous chromatography capacity expansion accelerates ahead of scheduled biosimilar approval timelines across major producing regions. The bear case near 7.3 percent materialises if biopharmaceutical capital budgets tighten enough that continuous system adoption is delayed, extending manufacturer reliance on conventional batch chromatography longer than expected across cost-sensitive smaller manufacturers.

Continuous Bioprocessing Reshapes Purification Standards

Preparative and process chromatography has moved from a batch-oriented purification step into a specification-sensitive continuous manufacturing platform faster than most process engineers expected, reshaping how suppliers plan resin and system investment. Systems that would have been operated as fixed stainless-steel installations a decade ago are increasingly evaluated on documented process intensification and cost-of-goods reduction because biologics manufacturers treat continuous chromatogra
MARKET CONCENTRATION48%Five suppliers hold a moderate combined global share
AVERAGE SYSTEM COST$1.4 million/unitReflects a standard process-scale chromatography system price today
NORTH AMERICA MANUFACTURING SHARE30%Deepest biologics manufacturing capacity found anywhere in the world
RESIN COST SHARE41%Specialty affinity and ion exchange resin sourcing dominates cost
SINGLE-USE ADOPTION RATE33%Share of installed capacity using disposable chromatography column formats
RESIN LIFETIME CYCLE50-200 cyclesTypical duration before a standard affinity resin requires replacement
Commercial activity concentrates in standard affinity and ion exchange chromatography, where resin sourcing scale and system engineering give the five largest suppliers durable advantages on large biologics manufacturer and contract development organization contracts. Continuous and multi-column systems remain a smaller but fast-scaling category, increasingly specified directly by process development teams. Size exclusion and hydrophobic interaction systems round out demand across specialty polishing applications.
The next decade will be shaped less by incremental resin chemistry refinement than by how fast suppliers can qualify continuous system capacity at batch-chromatography cost parity. Suppliers that can bundle certified single-use consumables with continuous multi-column platforms capture disproportionate share of new biologics manufacturer contracts, particularly as biosimilar approval activity accelerates across major regulatory jurisdictions.
"Process chromatography used to mean a single large stainless-steel column running one batch at a time. Now a biologics facility runs multiple smaller columns in continuous rotation to cut purification cost per gram."
Director, Biopharmaceutical Manufacturing Practice · MMA Biopharmaceutical Downs

Market Trends

Continuous Multi-Column Systems Become Standard for Process Intensification

Biologics manufacturers across major producing regions increasingly specify continuous multi-column chromatography systems as a replacement for conventional batch purification, making process intensification a growing default for monoclonal antibody manufacturing rather than a discretionary upgrade manufacturers can defer indefinitely. Manufacturers with the broadest continuous adoption report that documented cost-of-goods reduction and resin utilization efficiency have become factors cited in new capital equipment decisions, ahead of raw unit cost. Cytiva and Merck KGaA both report that continuous system orders have grown faster than standard batch orders across their major manufacturing accounts recently, especially in monoclonal antibody programmes.
Market Impact: Sustains a 53% production-linked de

Single-Use Consumables Expand Flexible Manufacturing Adoption

Contract development and manufacturing organizations across major producing regions continue to expand single-use chromatography column adoption behind rising multi-product facility flexibility requirements that fixed stainless-steel installations cannot fully accommodate, extending demand into manufacturing volume that previously relied on dedicated fixed systems alone. Organizations serving high-growth biosimilar markets report that column specification requirements are typically driven more by changeover speed than by discretionary purchasing preferences. Sartorius AG and Repligen Corporation both report that single-use orders are a growing share of their chromatography business today, and both suppliers expect that share to keep expanding as multi-product facility investment continues.
Market Impact: Adds 11pp to addressable biosimilar

Market Opportunities and Growth Drivers

Monoclonal Antibody Pipeline Volume Sustains Baseline System Demand

Rising monoclonal antibody and biosimilar pipeline volume across major biopharmaceutical systems continues to sustain preparative and process chromatography demand regardless of broader manufacturing capital spending cycles, since every commercial-scale biologics batch represents committed downstream purification demand tied to regulatory approval rather than discretionary purchasing. Manufacturers managing large-scale biologics production report that system specification requirements are typically driven more by production volume than by discretionary capital preferences. This production-linked demand gives chromatography suppliers unusually predictable baseline revenue compared with other bioprocessing categories that depend more heavily on discretionary capital equipment replacement cycles.
Market Impact: Raises input cost volatility by 17%

Biosimilar Approval Activity Broadens the Addressable Market

Continued biosimilar regulatory approval activity across major biopharmaceutical markets continues to expand demand for process-scale chromatography, and expanded approval activity increasingly makes continuous purification accessible and necessary for manufacturers that historically relied exclusively on conventional batch chromatography due to lower awareness of continuous-process performance alternatives. Manufacturers serving high-growth biosimilar markets report that system specification decisions now weigh cost-of-goods reduction as heavily as upfront capital cost. Several regulatory agencies have published expedited biosimilar review pathways, shortening the time between clinical validation and commercial-scale production approval. Suppliers serving these manufacturers report more reliable volume forecasting as a result.
Market Impact: Limits smaller-manufacturer adoptio

Market Restraints and Challenges

Specialty Resin Price Volatility Squeezes Manufacturer Margins

Preparative and process chromatography suppliers face specialty affinity and ion exchange resin input cost volatility that scale production does not fully escape, and the root cause of the margin pressure is a supply constraint: specialty protein ligand and base-matrix manufacturing capacity has not expanded fast enough to match rising biologics production demand, leaving suppliers exposed to price spikes during tight specialty materials market conditions. That constraint slows how quickly suppliers can hold pricing stable for large manufacturer contracts, forcing suppliers to pass cost increases through to buyers mid-contract. Suppliers including Merck KGaA mitigate this by expanding long-term resin supply agreements.
Market Impact: Cuts resin use by 26%

Continuous Process Validation Complexity Limits Smaller Manufacturer Adoption

Continuous chromatography validation requires extensive process characterization documentation that many smaller biologics manufacturers cannot generate against thin regulatory affairs budgets, and the root cause of the constraint is a genuine evidentiary issue: regulatory agencies have expanded continuous-process validation documentation requirements faster than many smaller manufacturers can resource, raising the compliance bar for continued approval. That constraint slows how quickly smaller manufacturers can match the validation track record that larger biopharmaceutical companies already provide, forcing smaller manufacturers to extend limited-scope batch chromatography beyond preferred expansion timelines. Suppliers including Sartorius AG are mitigating the constraint by expanding shared validation support programmes.
Market Impact: Expands single-use adoption by 16pp
3 additional market trends, 4 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

MMA segments the preparative and process chromatography market by separation mechanism and manufacturing format type, the classification biologics manufacturers and process development teams actually specify and purchase against across every major downstream purification application worldwide. Six categories cover the addressable market, spanning affinity, ion exchange, and continuous formats, and MMA selects the two fastest-growing categories for detailed narrative treatment below.
preparative-and-process-chromatography-market-market-share-analysis-1787307669941

Continuous and Multi-Column Chromatography Systems

Continuous and multi-column chromatography systems are growing fastest because they directly address the process intensification and cost-of-goods reduction requirements that conventional batch chromatography cannot satisfy under tightening biosimilar cost-competition pressure. Cytiva and Merck KGaA both dominate this segment given their continuous system engineering investment and the process development team relationships that newer entrants find difficult to replicate quickly at comparable regulatory validation depth. Capital intensity remains a consideration, since continuous system installation costs differ substantially across facility configurations. Growth here is expected to broaden as additional biologics manufacturers finalize continuous purification relationships, treating process intensification as the general default rather than a premium option reserved for flagship large-scale facilities alone.
CAGR 12.8%

Single-Use Chromatography Columns and Consumables

Single-use chromatography columns and consumables are the second-fastest-growing category as contract development and manufacturing organizations increasingly specify disposable formats that conventional stainless-steel fixed installations cannot provide as effectively for rapid multi-product facility changeover. Sartorius AG and Repligen Corporation both dominate this segment given their single-use engineering expertise and the contract manufacturing relationships that newer entrants find difficult to match at comparable regulatory documentation levels. Smaller regional manufacturers without dedicated single-use capability face growing pressure to partner or cede this category to larger competitors with established production capacity. Growth here tracks closely with how fast facilities convert legacy fixed-installation protocols to single-use pathways, and how quickly resin suppliers qualify new formats against evolving regulatory validation standards.
CAGR 11.4%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America leads global preparative and process chromatography demand, home to the deepest biologics manufacturing capacity in the world today. East Asia grows fastest behind expanding biosimilar manufacturing investment and rising healthcare infrastructure spending across the region. Western Europe follows on established biopharmaceutical manufacturing depth.

North America

The United States' concentration of biologics manufacturing capacity and monoclonal antibody production anchors North American demand through the deepest bioprocessing infrastructure of any producing region, drawing on decades of accumulated purification engineering expertise that domestic and multinational suppliers both compete to serve. Canada's expanding biologics manufacturing sector, anchored by strong government life sciences investment, represents one of the region's most sophisticated markets for continuous chromatography adoption. Cytiva and Merck KGaA's domestic distribution and technical support infrastructure both give American manufacturers faster access to newly qualified resin systems than suppliers serving more distant regional markets can typically offer. Mexico's growing contract manufacturing sector adds a smaller layer of regional demand, drawing increasingly on cross-border supply relationships with US-based resin distributors.
Share: 30% | CAGR: 7.8% (2026 to 2036)

Western Europe

Germany and Switzerland anchor Western European demand, both home to mature biopharmaceutical manufacturing sectors that pioneered modern continuous chromatography standards and increasingly specify certified process intensification for regulatory and cost-of-goods compliance. The European Union's pharmaceutical manufacturing regulatory framework gives suppliers with established European quality validation infrastructure a large, relatively homogeneous compliance market to serve compared with the more fragmented regulatory landscape found in other regions. The United Kingdom's advanced national biologics infrastructure, among the most developed globally, gives British manufacturers a demonstrated continuous chromatography advantage other markets increasingly reference. Italy's growing bioprocessing investment is accelerating adoption behind updated national manufacturing programmes. Spain's expanding biologics network rounds out the region's demand base.
Share: 24% | CAGR: 7.1% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
preparative-and-process-chromatography-market-country-cagr-analysis-1787307670796

Continuous System Depth and Manufacturer Relationship Reach

Suppliers extract value less through raw resin unit pricing than through building continuous system engineering capability, deepening biologics manufacturer relationships, and bundling validation support into long-term supply programmes across every major market. The levers below describe how each part of the value chain captures its share of the process-intensification-driven transition now underway across chromatography production today.

Continuous System Investment Captures Manufacturer Loyalty

Suppliers that build comprehensive continuous multi-column engineering and process control software capability fastest capture a disproportionate share of new biologics manufacturer relationships, since process development teams rarely switch system suppliers once a validated continuous protocol has been fully integrated into their regulatory filing. Cytiva and Merck KGaA both report that manufacturers adopting their continuous systems earliest carry meaningfully higher repeat purchase rates, roughly 24 percent higher than manufacturers using competitor conventional batch systems. This first-mover dynamic makes continuous system investment a strategic priority that can outweigh incremental unit price differences between competing suppliers.
Market Impact: Wins roughly 24% higher repeat purc

Long-Term Resin Supply Agreements Anchor Cost Stability

Suppliers that build long-term specialty affinity and ion exchange resin supply agreements capture years of predictable input cost stability that spot-market-dependent competitors cannot match, since every batch of contracted resin secured reduces exposure to periodic price spikes tied to global specialty materials market cycles. Bio-Rad Laboratories Inc and Repligen Corporation have both prioritised long-term supply agreements because cost stability now represents a growing share of total margin protection, exceeding the benefit of incremental capacity expansion within roughly 3 years of investment. Suppliers without strong supply agreement capability find it difficult to match the margin stability that leading competitors generate.
Market Impact: Stabilizes input costs within rough

Regulatory Validation Support Deepens Manufacturer Relationships

Suppliers that build dedicated continuous-process validation and regulatory documentation support capability into supply agreements capture deeper manufacturer relationships than equipment-only competitors, since regulatory affairs teams increasingly value integrated validation support for reducing their own internal compliance burden. Sartorius AG and Cytiva have both expanded validation capability specifically because bundled offerings raise average contract value by roughly 15 percent compared with equipment-only sales, giving suppliers a considerably stronger position during contract renewal negotiations. This bundling strategy requires sustained validation investment, but it creates switching costs that meaningfully raise manufacturer retention above equipment-only competitors' typical account longevity.
Market Impact: Raises average contract value by ro

Shared Pilot Access Reduces Smaller Manufacturer Risk

Suppliers that build shared continuous chromatography pilot access arrangements cut smaller manufacturer adoption risk by roughly 19 percent compared with suppliers requiring fully independent system investment, a difference that matters considerably to manufacturers managing budget-constrained expansion timelines. Repligen Corporation and Bio-Rad Laboratories Inc have both invested in expanding shared pilot access capability specifically to capture this risk-sharing value, recognising that fully independent system investment carries direct commercial cost for manufacturers running low-volume specialty biologics programmes. Suppliers without comparable shared access capability find it difficult to compete for smaller independent manufacturer contracts.
Market Impact: Cuts adoption risk by roughly 19% a

Who Controls the Margin Pool

Five suppliers, Cytiva, Merck KGaA, Sartorius AG, Bio-Rad Laboratories Inc, and Repligen Corporation, hold roughly 48 percent of global preparative and process chromatography revenue, a moderate concentration reflecting an industry still populated by numerous specialized resin and system manufacturers. The gap to challengers like Tosoh Corporation and Purolite Corporation is narrower than the headline share suggests, since the remainder sits with specialized regional manufacturers rather than gl
Current competitive activity centres on three fronts: building continuous system engineering capability to win manufacturer loyalty, expanding long-term resin supply agreements, and bundling regulatory validation support into long-term supply agreements. Suppliers are expanding shared pilot access capability to reduce smaller manufacturer risk and strengthen independent biologics manufacturer contract positioning.

Emerging pressure comes from regional Asian and European resin specialists expanding capability to serve narrower, higher-growth continuous and single-use applications rather than competing across the conventional generic batch chromatography spectrum. Rankings are most likely to shift in continuous and single-use categories, where system engineering speed rather than raw production scale determine competitive position, leaving room for suppliers that move fastest on validation capability to gain share from legacy incumbents.
preparative-and-process-chromatography-market-company-positioning-matrix-1787307671726

Competitive Moat and Risk Dimensions

CYTIVA

Moat: Broadest Global Bioprocessing Portfolio

Cytiva operates the broadest bioprocessing chromatography portfolio spanning more separation mechanisms and regions than any single competitor, giving it cross-selling advantages that narrower regional suppliers cannot match. That portfolio breadth, built over decades of dedicated purification engineering investment, is difficult for newer entrants to replicate quickly.
CYTIVA

Risk: Complex Portfolio Integration Overhead

Cytiva's broader bioprocessing portfolio creates integration and coordination overhead when managing chromatography-specific product lines alongside its many other bioprocessing categories, occasionally leaving the company slower to prioritise chromatography-specific innovation. Narrower application-focused competitors can sometimes respond faster with more coherent, purpose-built offerings tailored to specific manufacturer needs.
REPLIGEN CORPORATION

Moat: Deep Single-Use Engineering Heritage

Repligen Corporation's decades-deep single-use bioprocessing engineering heritage gives it specification advantages that competitors without comparable large-scale disposable format integration history cannot match, letting it win specification decisions on flexibility credibility as much as resin reach. That heritage, built over years of dedicated single-use investment, gives Repligen Corporation a durable advantage in flexible manufacturing categories.
REPLIGEN CORPORATION

Risk: Narrower Fixed-Installation Distribution

Repligen Corporation's fixed-installation chromatography distribution footprint remains narrower than competitors like Cytiva, leaving it more dependent on single-use revenue than suppliers with broader fixed-installation distribution reach. A slowdown in single-use adoption would disproportionately affect Repligen Corporation relative to more distribution-diversified global rivals with broader account bases to fall back on.

Players Tracked

Prominent Players

Cytiva
Merck KGaA
Sartorius AG
Bio-Rad Laboratories Inc
Repligen Corporation

Other Key Players

Tosoh Corporation
Purolite Corporation
Thermo Fisher Scientific Inc
Waters Corporation
Agilent Technologies Inc
YMC Co Ltd
JSR Corporation
Avantor Inc
Novasep Holding SAS
Semba Biosciences Inc
Knauer Wissenschaftliche Geraete GmbH
Gilson Inc
Buchi Labortechnik AG
ChromaTan Corporation
Pall Corporation

Recent Developments

FEBRUARY 2026

Cytiva Launches Expanded Continuous Chromatography Platform

Cytiva launched an expanded continuous multi-column chromatography platform in February 2026, adding dedicated process intensification modules separate from its existing standard batch offerings. The launch addresses growing biologics manufacturer demand for certified cost-of-goods reduction ahead of expanding biosimilar competition across major biopharmaceutical markets globally today.
Signal: Confirms that continuous chromatography ca
SEPTEMBER 2025

Merck KGaA Signs Major Biologics Manufacturer Supply Agreement

Merck KGaA signed a multi-year resin and system supply agreement with a major biologics manufacturer in September 2025, committing to provide certified affinity chromatography systems across the manufacturer's expanding monoclonal antibody production locations. The agreement covers multiple regional manufacturing sites and represents one of the largest supply commitments recorded.
Signal: Signals that major biologics manufacturers
APRIL 2025

Sartorius AG Expands Single-Use Column Manufacturing Capacity

Sartorius AG commissioned expanded single-use chromatography column manufacturing capacity in April 2025, adding dedicated production lines serving growing demand from contract manufacturing organizations. The expansion positions Sartorius AG to capture growing demand from manufacturers converting legacy fixed-installation specifications to certified compliant single-use sourcing nationwide, ahead of tightening validation timelines.
Signal: Marks continued investment in single-use c

Specialty Resin and Ligand Component Cost

Specialty affinity ligands, ion exchange base-matrix materials, and single-use column housing components represent the largest cost inputs for preparative and process chromatography production, accounting for 41 percent of total supplier cost, sourced from a global specialty biomaterials market subject to cost volatility. Regulatory compliance documentation and process validation testing infrastructure add a cost category for suppliers expanding continuous product lines.
Specialty affinity ligand prices spiked through 2022 as global biomaterials supply chains faced disruption amid competition for limited high-purity protein ligand capacity affecting multiple biopharmaceutical categories simultaneously, and Cytiva's fiscal year 2022 annual report cited elevated raw material acquisition costs as a constraint on bioprocessing segment margins despite underlying demand. Suppliers responded by expanding long-term resin supply agreements and redesigning ligand formulations around more available material grades.

Vertically integrated suppliers with captive resin sourcing capacity, including Cytiva and Merck KGaA, absorb material cost volatility more predictably than smaller specialized manufacturers who compete for open-market ligand materials at spot rates during periods of tight availability. That gap gives integrated suppliers a cost-stability advantage over smaller independent manufacturers, particularly during the resin price cycles that squeeze margins across the specialty bioprocessing manufacturing industry.
preparative-and-process-chromatography-market-cost-volatility-analysis-1787307672056

Expanding Long-Term Resin Supply Agreements

Leading suppliers are expanding long-term specialty affinity and ion exchange resin supply agreements across multiple sourcing markets to reduce reliance on single-source spot purchasing, converting a variable input cost exposure into a more predictable, diversified material base across their production network. This diversification strategy has proven valuable during periods of resin shortage that squeeze non-diversified competitors hardest.

Redesigning Ligands Around Available Material Grades

Suppliers are redesigning ligand manufacturing processes and formulations around more readily available base-matrix grades to reduce exposure to single-specification shortages that have periodically delayed production schedules across the wider industry. This redesign investment requires sustained process resources but reduces long-term exposure to material scarcity that has repeatedly constrained output across the broader supplier base.

Vertically Integrating Resin Sourcing Capacity

Larger suppliers are acquiring or expanding their own dedicated resin sourcing and ligand manufacturing capacity to reduce dependence on open-market material purchasing, trading some flexibility for supply certainty and cost predictability across their production network overall. Smaller specialized manufacturers without comparable sourcing scale remain more exposed to material cost volatility during periods of tight global market availability.

Portfolio Architecture for Margin Defence

Preparative and process chromatography suppliers operate across three margin tiers built around process depth and format sophistication rather than simple unit volume. Commodity-adjacent standard ion exchange systems sit at the volume base, certified affinity and single-use systems occupy the middle at meaningfully firmer margins, and next-generation continuous multi-column platforms sit at the top, commanding premium pricing that few conventional suppliers can currently match. Most established
The volume-premium tension plays out most visibly in how suppliers allocate scarce engineering and R&D resources: every production cycle dedicated to a standard ion exchange system is a cycle not available for higher-margin continuous multi-column platform development, so suppliers increasingly prioritise premium allocation even when it means directing standard customers toward longer lead times overall.

High-value margin pools concentrate in continuous multi-column platforms and certified single-use systems, both of which command pricing closer to specialty capital equipment economics than to standard commodity chromatography pricing. Suppliers that can move a manufacturer from conventional batch supply into a continuous relationship capture meaningfully more of total account value across the life of the contract.

Volume / Commodity-Adjacent Tier

Standard ion exchange chromatography systems sold at scale into routine biologics manufacturing applications, priced close to established commodity capital equipment benchmarks with limited technical differentiation between qualified suppliers competing mainly on service and delivery speed.
Gross Margin: 16-22%

Premium / Certified Tier

Certified affinity and single-use systems requiring extensive resin formulation and regulatory validation investment, commanding a defensible premium given the technical investment behind each qualified system. Buyers weigh compliance documentation and purification efficiency performance heavily.
Gross Margin: 24-32%

Sustainability / Regulatory / Next-Generation Tier

Next-generation continuous multi-column platforms carrying the deepest process control and software investment, sold primarily into biologics manufacturers' highest-visibility process intensification programmes. Pricing power here remains strong, and supply is still constrained enough that qualified suppliers rarely compete purely on price.
Gross Margin: 33-43%
preparative-and-process-chromatography-market-portfolio-architecture-1787307672870

High-value Sub-segments and Strategic Watch-out

Continuous Multi-Column Platforms

Continuous multi-column platforms carry the category's highest margins and fastest growth, driven by biologics manufacturers seeking documented cost-of-goods reduction outcomes beyond what conventional batch chromatography can provide alone. Early movers here are capturing outsized specification share ahead of slower-moving generalist competitors industry-wide, and that lead looks durable.
Gross Margin: 33-43%

Regulatory Validation Support Contracts

Continuous-process validation and regulatory documentation support service contracts carry strong margins and steady growth, anchored in multi-year relationships that renew predictably as manufacturers expand certified system specification across additional biologics programmes. Suppliers with proven validation platforms renew these agreements almost automatically over time each year.
Gross Margin: 24-32%

Standard Ion Exchange Systems

Standard ion exchange chromatography systems remain the category's volume anchor, growing steadily with overall biologics demand but carrying commodity-level margins that make it a scale rather than profit driver for most suppliers. Suppliers defend this tier mainly to preserve distribution reach and long-term manufacturer relationships.
Gross Margin: 16-22%

Regional Low-Cost Manufacturing Entrants

Specialized regional manufacturers focused narrowly on standard batch applications represent a long-term competitive threat to established diversified suppliers' pricing power, particularly as biologics manufacturers increasingly favour lower-cost qualified regional suppliers over general-purpose multinational supply for large-scale biosimilar programmes across every major producing and consuming market worldwide.
Gross Margin: 13-19%

From Fixed Installation to Process Partner

Preparative and process chromatography procurement is shifting from a fragmented fixed-installation purchase toward a process partnership that resembles an ongoing biologics manufacturer relationship more than a series of one-time capital equipment transactions. Suppliers that embed continuous system engineering and validation support into standard supply agreements lock in renewal revenue, while process development teams treat continuous chromatography specification as the starting assumption f
Adoption depth varies sharply by end-use vertical. Large monoclonal antibody and biosimilar manufacturers show the deepest reliance on continuous and single-use systems, since cost-of-goods consequences are most acute in categories facing direct pricing competition pressure. Standard vaccine and small-molecule API applications show steadier, less intensification-driven demand, since specification decisions there track cost and availability more than continuous process documentation requirements specifically.

A generational shift among process development leaders is reinforcing the trend. Younger leaders trained during the recent continuous-processing investment wave treat continuous-first specification as standard practice, while veteran engineers accustomed to batch protocols are adapting more slowly, defaulting to familiar fixed-installation sourcing until forced by a cost overrun or facility renewal cycle.
preparative-and-process-chromatography-market-end-use-penetration-index-1787307673728

Where MMA Sees the Real Opportunity

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / CONTINUOUS SYSTEM INVESTMENT

Build continuous capability ahead of intensification demand

Suppliers that build comprehensive continuous multi-column engineering and process control software capability now are positioned to capture new biologics manufacturer relationships meaningfully faster than suppliers dependent entirely on conventional, batch chromatography competing for the same compliance-driven specification decisions across every major biopharmaceutical market. This positioning matters more than competing purely on unit pricing, since continuous system capability, not raw production scale alone, increasingly determines which supplier wins large manufacturer contracts. MMA recommends prioritising continuous investment over incremental conventional capacity expansion in the current three-year window.
02 / LONG-TERM RESIN SUPPLY DEVELOPMENT

Build resin supply capability ahead of demand

Suppliers that build integrated long-term specialty resin supply agreement capability ahead of confirmed demand capture a disproportionate share of the cost stability that follows every ligand price cycle, since manufacturers rarely switch supply partners once a stable-cost relationship is validated against a specific production programme. Suppliers still relying on open-market resin purchasing are ceding margin protection to competitors already investing in supply capability. MMA views supply agreement investment as the highest-return near-term opportunity available within the category over the next three years.
03 / REGULATORY VALIDATION SERVICES

Bundle validation support into every manufacturer sale

Suppliers that bundle continuous-process validation and regulatory documentation support into every manufacturer sale capture deeper account penetration and higher switching costs than equipment-only competitors, providing a durable differentiation advantage that pure product suppliers cannot easily replicate. Suppliers concentrated purely in equipment sales face meaningfully more price-competitive dynamics than validation-focused competitors carrying broader account value and stronger renewal terms. MMA recommends building or acquiring validation capability as a durable differentiation strategy for suppliers currently overexposed to equipment-only competition today across the industry.
04 / SHARED PILOT ACCESS INVESTMENT

Build shared pilot access now

Smaller manufacturers managing budget-constrained expansion timelines increasingly require guaranteed continuous chromatography pilot access, and suppliers with established shared access capability face a genuinely lower-risk competitive position than competitors relying purely on fully independent system investment requirements. Competitors that moved early on shared access investment are capturing differentiated, multi-year manufacturer contract advantages years ahead of suppliers still exposed to independent-investment adoption risk today. MMA recommends prioritising shared access investment as a durable, relatively capital-efficient differentiation strategy available to suppliers of every size across the market today overall.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Preparative and Process Chromatography Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Preparative and Process Chromatography Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized regional biosimilar manufacturer operating multiple production locations across a single metropolitan corridor, facing rising cost-competition pressure to convert to continuous chromatography without a coordinated supplier transition strategy. The manufacturer reported annual downstream purification capital spending in the low tens of millions of dollars (client-reported, unverified by MMA) and had historically relied predominantly on conventional batch chromatography without a systematic continuous qualification programme.
STRATEGIC CHALLENGE
The manufacturer faced growing cost-competition pressure to standardize continuous chromatography protocols across multiple production locations simultaneously, but limited capital budget meant a phased supplier transition was unavoidable, requiring a defensible framework for prioritising which locations to convert first. Management needed a strategy that balanced regulatory filing timelines, transition cost, and staff retraining across a multi-year purification modernization programme.
MMA APPROACH
MMA's engagement team benchmarked available chromatography suppliers against the manufacturer's location-specific production volumes and cost-of-goods targets, interviewed suppliers to assess continuous validation track record, and modelled transition cost and margin impact across three prioritisation scenarios. The team recommended a phased conversion that prioritised the manufacturer's highest-volume locations first while securing supplier validation commitments ahead of the next regulatory filing cycle.
KEY FINDINGS
  1. Two of the manufacturer's production locations accounted for a disproportionate share of total purification volume (client-reported, unverified by MMA), making them clear priorities for continuous system investment.
  2. Suppliers offering integrated regulatory validation support delivered meaningfully faster conversion timelines than suppliers expecting the manufacturer to manage process characterization independently during the transition process.
  3. Continuous system costs for the manufacturer's highest-volume location exceeded initial budgeting assumptions the planning team had used by a wider margin than anticipated.
  4. Early supplier engagement during the conversion process reduced total modernization cost compared with the manufacturer's historical practice of finalising specifications before requesting supplier quotes.
CLIENT PROFILE
The client is a mid-sized regional biosimilar manufacturer operating multiple production locations across a single metropolitan corridor, facing rising cost-competition pressure to convert to continuous chromatography without a coordinated supplier transition strategy. The manufacturer reported annual downstream purification capital spending in the low tens of millions of dollars (client-reported, unverified by MMA) and had historically relied predominantly on conventional batch chromatography without a systematic continuous qualification programme.
STRATEGIC CHALLENGE
The manufacturer faced growing cost-competition pressure to standardize continuous chromatography protocols across multiple production locations simultaneously, but limited capital budget meant a phased supplier transition was unavoidable, requiring a defensible framework for prioritising which locations to convert first. Management needed a strategy that balanced regulatory filing timelines, transition cost, and staff retraining across a multi-year purification modernization programme.
MMA APPROACH
MMA's engagement team benchmarked available chromatography suppliers against the manufacturer's location-specific production volumes and cost-of-goods targets, interviewed suppliers to assess continuous validation track record, and modelled transition cost and margin impact across three prioritisation scenarios. The team recommended a phased conversion that prioritised the manufacturer's highest-volume locations first while securing supplier validation commitments ahead of the next regulatory filing cycle.
KEY FINDINGS
  1. Two of the manufacturer's production locations accounted for a disproportionate share of total purification volume (client-reported, unverified by MMA), making them clear priorities for continuous system investment.
  2. Suppliers offering integrated regulatory validation support delivered meaningfully faster conversion timelines than suppliers expecting the manufacturer to manage process characterization independently during the transition process.
  3. Continuous system costs for the manufacturer's highest-volume location exceeded initial budgeting assumptions the planning team had used by a wider margin than anticipated.
  4. Early supplier engagement during the conversion process reduced total modernization cost compared with the manufacturer's historical practice of finalising specifications before requesting supplier quotes.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 6): Convert the two highest-volume production locations to continuous chromatography immediately, securing early cost-of-goods gains. Phase 2: Phase 2 (Months 7 to 15): Secure validation commitments and convert the remaining locations, sequencing by volume and budget availability. Phase 3: Phase 3 (Months 16 to 20): Complete network-wide conversion and consolidate all supplier relationships across the manufacturer's full production portfolio.
OUTCOME
Following the engagement, the client reported a meaningful reduction in cost-of-goods and improved margin resilience across its converted locations, avoiding the pricing-competitiveness risk it had initially feared (client-reported, unverified by MMA). The phased transition reduced total conversion cost relative to the manufacturer's budget and established supplier relationships the manufacturer has since extended across its broader production portfolio.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Preparative and Process Chromatography Market?

The global market reached approximately $5.2 billion in 2026. Demand is concentrated in standard affinity and ion exchange chromatography, with continuous multi-column systems emerging as the primary growth driver.

How large will the Preparative and Process Chromatography Market be by 2036?

MMA projects the market will reach approximately $11.9 billion by 2036. That represents roughly a 2.28 times increase in 2026 revenue across the ten-year forecast period.

What is the CAGR for the Preparative and Process Chromatography Market 2026 to 2036?

The base case compound annual growth rate is 8.6 percent. Bull and bear scenarios range from roughly 7.3 percent to 9.9 percent depending on continuous system expansion pace and biosimilar approval trends.

Which segment is growing fastest?

Continuous and multi-column chromatography systems are growing fastest, at roughly 1.49 times the overall market rate. Process intensification and cost-of-goods reduction requirements are the primary drivers behind that outperformance.

Who are the major companies in the Preparative and Process Chromatography Market?

Five global suppliers, led by Cytiva, Merck KGaA, and Sartorius AG, lead the market. Together the top five hold roughly 48 percent of global preparative and process chromatography revenue.

Which country is growing fastest?

China is among the fastest-growing markets, driven by continued large-scale biosimilar and monoclonal antibody manufacturing expansion. Its chromatography demand is expanding at roughly 11.6 percent annually.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Product Type

  • Affinity Chromatography Systems and Resins
  • Ion Exchange Chromatography Systems and Resins
  • Size Exclusion Chromatography Systems and Resins
  • Continuous and Multi-Column Chromatography Systems
  • Single-Use Chromatography Columns and Consumables
  • Hydrophobic Interaction Chromatography Systems and Resins

By End-Use Industry

  • Biologics and Biopharmaceutical Manufacturers
  • Contract Development and Manufacturing Organizations
  • Vaccine Manufacturers
  • Academic and Government Research Institutions

By Commercial Dimension

  • Direct Supplier-to-Manufacturer Sales
  • Regulatory Validation and Compliance Support Services
  • Distributor and Wholesaler Channel Sales
  • Contract System Leasing Arrangements

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The preparative and process chromatography market covers preparative and process-scale liquid chromatography systems, resins, and consumables used for downstream purification of biologics, monoclonal antibodies, vaccines, and small-molecule active pharmaceutical ingredients in commercial and clinical-scale manufacturing. It excludes analytical-scale chromatography instruments used for quality control and research testing, gas chromatography systems, and chromatography media used exclusively in non-pharmaceutical industrial separation applications.
Quantitative Units
USD billions (current prices); annual installed capacity where applicable
Segmentation Dimensions
By Product Type; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, Canada, Mexico, Germany, Switzerland, United Kingdom, Italy, Spain, China, South Korea, Japan, Taiwan, India, Australia, Singapore, Thailand, Vietnam, Indonesia, Brazil, Argentina, Colombia, Chile, Saudi Arabia, UAE, Egypt, South Africa, Poland, Czech Republic, Hungary, Romania, and additional markets relevant to this sector
Key Companies Profiled
Cytiva, Merck KGaA, Sartorius AG, Bio-Rad Laboratories Inc, Repligen Corporation, Tosoh Corporation, Purolite Corporation, Thermo Fisher Scientific Inc, Waters Corporation, Agilent Technologies Inc, YMC Co Ltd, JSR Corporation, Avantor Inc, Novasep Holding SAS, Semba Biosciences Inc, Knauer Wissenschaftliche Geraete GmbH, Gilson Inc, Buchi Labortechnik AG, ChromaTan Corporation, Pall Corporation
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-247
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Preparative and Process Chromatography Market Report (2026 to 2036).

The full report delivers a complete quantitative and qualitative assessment of the global preparative and process chromatography market across all seven regions. It includes detailed country-level sizing for the fifteen largest producing and consuming markets, full profiles of all twenty companies named in the competitive landscape, and a complete database of corporate developments tracked over the trailing eighteen months. Analysts provide segment-by-segment margin benchmarking derived from primary interviews with forty-seven bioprocessing and procurement experts, alongside a continuous-process regulatory tracker covering major jurisdictions. Buyers receive access to underlying data tables and a ninety-minute analyst briefing call included with purchase.
Country-level sizing for fifteen major producing and consuming markets
Full profiles of all twenty companies profiled
Continuous-process and single-use regulatory tracker across major jurisdictions
Segment-level margin benchmarking from primary expert interviews
Eighteen-month corporate development and capacity expansion database
Ninety-minute analyst briefing call included with purchase

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts